Bio-Techne Highlights Progress on Climate, Innovation, and Culture in 2025 Sustainability Report
Bio-Techne (NASDAQ: TECH) has released its 2025 Corporate Sustainability Report, highlighting significant progress in environmental stewardship and innovation. The company achieved a notable 40% reduction in Scope 1 and 2 emissions through renewable electricity adoption at its Minneapolis headquarters.
Under CEO Kim Kelderman's leadership, Bio-Techne has committed to setting science-based GHG reduction targets for validation by SBTi in 2026. The company continues to advance breakthroughs in various diseases while implementing enhanced governance measures, including new Board oversight of AI and completion of climate assessments.
The report emphasizes Bio-Techne's focus on sustainable innovation across its life sciences portfolio, particularly in cell therapy, proteomic instruments, and precision diagnostics.
Bio-Techne (NASDAQ: TECH) ha pubblicato il suo Rapporto 2025 sulla Sostenibilità Aziendale, evidenziando notevoli progressi nella gestione ambientale e nell'innovazione. L'azienda ha raggiunto una riduzione notevole del 40% delle emissioni Scope 1 e 2 grazie all'uso di energia rinnovabile presso la sede di Minneapolis. Sotto la guida dell'amministratore delegato Kim Kelderman, Bio-Techne si è impegnata a definire obiettivi scientifici di riduzione delle emissioni di GHG per la validazione da parte di SBTi nel 2026. L'azienda continua a far avanzare scoperte in diverse malattie, implementando al contempo misure di governance potenziate, tra cui una nuova supervisione del Consiglio sull'IA e il completamento delle valutazioni climatiche. Il rapporto sottolinea l'attenzione di Bio-Techne all'innovazione sostenibile nel proprio portafoglio di scienze della vita, in particolare in terapia cellulare, strumenti proteomici e diagnostica di precisione.
Bio-Techne (NASDAQ: TECH) ha publicado su Informe de Sostenibilidad Corporativa 2025, destacando avances significativos en la administración ambiental y la innovación. La empresa logró una notable reducción del 40% de las emisiones de Alcance 1 y 2 gracias a la adopción de electricidad renovable en su sede de Minneapolis. Bajo la dirección del CEO Kim Kelderman, Bio-Techne se ha comprometido a establecer objetivos de reducción de gases de efecto invernadero basados en la ciencia para su validación por SBTi en 2026. La empresa continúa impulsando avances en diversas enfermedades mientras implementa mejoras en la gobernanza, incluida la nueva supervisión de IA por parte de la Junta y la finalización de evaluaciones climáticas. El informe hace hincapié en el enfoque de Bio-Techne hacia la innovación sostenible en su portafolio de ciencias de la vida, especialmente en terapia celular, instrumentos proteómicos y diagnóstico de precisión.
Bio-Techne (NASDAQ: TECH)가 2025년 기업 지속 가능성 보고서를 발표하며 환경 관리와 혁신에서 중요한 진전을 강조했습니다. 미니애폴리스 본사의 재생에너지 도입으로 Scope 1 및 2 배출량이 40% 감소했습니다. CEO 김 켈더먼의 지휘 아래 Bio-Techne는 2026년 SBTi의 검증을 위한 과학 기반 GHG 감축 목표를 설정하기로 약속했습니다. 회사는 다양한 질병 분야의 돌파구를 지속 추진하는 한편, 이사회가 AI를 감독하는 새로운 거버넌스 체계 도입과 기후 평가의 완료를 포함한 거버넌스 강화도 진행하고 있습니다. 보고서는 생명과학 포트폴리오 전반에 걸친 지속 가능한 혁신에 초점을 맞추고 있으며, 특히 세포 치료, 프로테오믹 도구, 정밀 진단에 주력합니다.
Bio-Techne (NASDAQ: TECH) a publié son Rapport 2025 sur la durabilité d'entreprise, mettant en évidence des progrès importants en matière de préservation de l'environnement et d'innovation. L'entreprise a réalisé une réduction notable de 40 % des émissions de Scope 1 et 2 grâce à l'adoption d'électricité renouvelable à son siège de Minneapolis. Sous la direction du PDG Kim Kelderman, Bio-Techne s'est engagée à fixer des objectifs de réduction des gaz à effet serre basés sur les sciences pour une validation par le SBTi en 2026. L'entreprise continue de faire progresser les avancées dans diverses maladies tout en mettant en œuvre des mesures de gouvernance renforcées, y compris une nouvelle supervision du conseil sur l'IA et l'achèvement des évaluations climatiques. Le rapport met l'accent sur l'innovation durable dans son portefeuille de sciences de la vie, notamment dans la thérapie cellulaire, les instruments protéomiques et le diagnostic de précision.
Bio-Techne (NASDAQ: TECH) hat seinen 2025 Corporate Sustainability Report veröffentlicht und dabei bedeutende Fortschritte im Umweltmanagement und in der Innovation hervorgehoben. Das Unternehmen erreichte eine bemerkenswerte Reduzierung der Scope-1- und Scope-2-Emissionen um 40% durch den Einsatz erneuerbarer Elektrizität am Hauptsitz in Minneapolis. Unter der Führung von CEO Kim Kelderman hat Bio-Techne sich verpflichtet, science-based GHG-Reduktionsziele für die Validierung durch SBTi im Jahr 2026 festzulegen. Das Unternehmen setzt weiterhin Durchbrüche in verschiedenen Krankheitsbereichen um, während es verbesserte Governance-Maßnahmen implementiert, darunter eine neue Vorstandsbefugnis bei KI und der Abschluss von Klimabewertungen. Der Bericht betont Bio-Technes Fokus auf nachhaltige Innovationen im Life-Science-Portfolio, insbesondere in der Zelltherapie, Proteomik-Instrumenten und Präzisionsdiagnostik.
نشرت Bio-Techne (ناسداك: TECH) تقريرها لعام 2025 حول الاستدامة المؤسسية، مبرزة تقدمًا كبيرًا في الحفظ البيئي والابتكار. حققت الشركة انخفاضًا ملحوظًا بنسبة 40% في انبعاثات النطاق 1 و2 من خلال اعتماد الكهرباء المتجددة في مقرها في مينيابوليس. وتحت قيادة الرئيس التنفيذي كيم كيلدرمان، تعهدت Bio-Techne بوضع أهداف تقليل للغازات الدفيئة تعتمد على العلم للتحقق من قبل SBTi في 2026. تواصل الشركة دفع الابتكارات في أمراض متنوعة مع تنفيذ إجراءات حوكمة محسنة، بما في ذلك الإشراف الجديد لمجلس الإدارة على الذكاء الاصطناعي وإكمال تقييمات المناخ. يركّز التقرير على الابتكار المستدام عبر محفظة العلوم الحياتية، لا سيما في العلاج الخلوي، وأدوات البروتيوم، والتشخيص الدقيق.
Bio-Techne（纳斯达克：TECH）发布了2025年企业可持续性报告，突显在环境管理与创新方面的显著进展。公司通过在明尼阿波利斯总部采用可再生能源，达到40%的Scope 1和2排放量下降。在首席执行官金·凯尔德曼的领导下，Bio-Techne承诺在2026年获得SBTi验证的科学基础温室气体减排目标。公司继续在多种疾病领域推进突破性研究，同时加强治理措施，包括董事会对人工智能的新监督以及气候评估的完成。报告强调Bio-Techne在生命科学组合中的可持续创新，尤其是在细胞治疗、蛋白质组学仪器和精准诊断方面。
- Achieved 40% reduction in Scope 1 and 2 emissions enterprise-wide
- Committed to science-based GHG reduction targets for validation by SBTi in 2026
- Implemented enhanced governance measures including AI oversight
- Continued development of breakthrough treatments for multiple diseases
- None.
Company advances transition to renewable electricity and sets a pathway to science-based emissions reductions
"As a global innovator in life sciences, our mission is to improve the quality of life by catalyzing advances in science and medicine," said Kim Kelderman, President and Chief Executive Officer of Bio-Techne. "We recognize that human health and the environment are intrinsically connected. By aligning our science with sustainable business practices, we not only unlock potential for better health outcomes, but also create lasting value for our employees, empower our customers, and strengthen the communities in which we live and work."
Highlights from Bio-Techne's 2025 Sustainability Report demonstrate measurable progress and bold commitments, including:
- Ongoing development and commercialization of breakthroughs in cancer, diabetes, neurodegenerative, autoimmune, and rare diseases—transforming diagnosis and care for millions worldwide.
- An estimated
40% reduction in Scope 1 and 2 emissions enterprise-wide, driven by the transition to100% renewable electricity at the company'sMinneapolis headquarters.⃰ - Commitment to set Scope 1, 2, and 3 greenhouse gas (GHG) reduction targets, with submission for validation to the Science Based Targets Initiative (SBTi) in 2026.
- Enhanced governance measures, including new Board oversight of artificial intelligence and completion of the first double materiality and climate assessments to guide sustainability priorities.
- Investment in culture and careers, with development and learning opportunities designed to empower teams under Bio-Techne's EPIC values—Empowerment, Passion, Innovation, and Collaboration
Bio-Techne's sustainability initiatives also fuel innovation across its life sciences portfolio, driving advances in cell therapy workflows, proteomic analytical instruments, spatial biology, and precision diagnostics—all developed with increased emphasis on efficiency and resource-conscious design.
"Our customers trust us to advance science responsibly, and we know that starts with our people," added Kelderman. "This report underscores our commitment to protecting the environment, supporting our employees and communities, and creating a workplace where diverse perspectives drive innovation and lasting impact."
The full 2025 Sustainability Report is available in the Corporate and Social Responsibility section of Bio-Techne's website.
*Based on Scope 1 and 2 market-based greenhouse gas emissions.
About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated over
Contact:
Corporate Communications
media.relations@bio-techne.com
David Clair, Vice President, Investor Relations
david.clair@bio-techne.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-highlights-progress-on-climate-innovation-and-culture-in-2025-sustainability-report-302565713.html
SOURCE Bio-Techne Corporation
FAQ
What environmental achievements did Bio-Techne (TECH) report in its 2025 Sustainability Report?
Who is the CEO of Bio-Techne (TECH) in 2025?
What governance changes did Bio-Techne (TECH) implement in 2025?
What are Bio-Techne's (TECH) key areas of innovation focus in 2025?
What are Bio-Techne's (TECH) EPIC values?
